SL 325
Alternative Names: SL-325Latest Information Update: 12 Jun 2026
At a glance
- Originator Shattuck Labs
- Class Anti-inflammatories; Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action Tumour necrosis factor ligand superfamily member 15 inhibitors; Tumour necrosis factor member 25 receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Inflammatory bowel diseases
Most Recent Events
- 08 Jun 2026 Adverse events, pharmacokinetics, pharmacodynamics and immunogenicity data from a phase-I trial in Inflammatory bowel diseases released by Shattuck Labs
- 05 Mar 2026 Shattuck plans the phase IIb RECEPTIVE-CD1 trial for Crohn’s disease in the US, Canada, and Europe (IV) in the third quarter of 2026
- 05 Sep 2025 Phase-I clinical trials in Inflammatory bowel diseases (In volunteers) in USA (Parenteral) (NCT07158437)